The response of eukaryotic topoisomerases to DNA damage

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1400, Issue 1-3, 1998, Pages 223-232

  Kingma, Paul S ^a   Osheroff, Neil ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer drug; Apurinic apyrimidinic site; Base mismatch; DNA damage; Topoisomerase; Ultraviolet photoproduct

Indexed keywords

DNA TOPOISOMERASE;

BASE MISPAIRING; CELL PROLIFERATION; DEAMINATION; DNA CLEAVAGE; DNA DAMAGE; DNA METABOLISM; DNA TRANSCRIPTION; ENZYME ACTIVE SITE; ENZYME INHIBITION; EUKARYOTE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; CELL DEATH; CHROMOSOME BREAKAGE; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; EUKARYOTIC CELLS; MUTAGENESIS; ULTRAVIOLET RAYS;

EID: 0032189576     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(98)00138-9     Document Type: Review

References (64)

1. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 65:1996;635-692.
2. N.R. Cozzarelli, J.C. Wang, DNA Topology and its Biological Effects, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1990.
3. Osheroff N., Zechiedrich E.L., Gale K.C. Catalytic function of DNA topoisomerase II. BioEssays. 13:1991;269-273.
4. Watt P.M., Hickson I.D. Structure and function of type II DNA topoisomerases. Biochem. J. 303:1994;681-695.
5. Gupta M., Fujimori A., Pommier Y. Eukaryotic DNA topoisomerase I. Biochim. Biophys. Acta. 1262:1995;1-14.
6. Champoux J.J. Mechanism of catalysis by eukaryotic DNA topoisomerase I. Adv. Pharmacol. 29:1994;71-82.
7. Andersen A.H., Svejstrup J.Q., Westergaard O. The DNA binding, cleavage, and religation reactions of eukaryotic topoisomerases I and II. Adv. Pharmacol. 29A:1994;83-101.
8. Sharma A., Mondragon A. DNA topoisomerases. Curr. Opin. Struct. Biol. 5:1995;39-47.
9. Sander M., Hsieh T. Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster. J. Biol. Chem. 258:1983;8421-8428.
10. Liu L.F., Rowe T.C., Yang L., Tewey K.M., Chen G.L. Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem. 258:1983;15365-15370.
11. Pulleyblank D.E., Shure M., Tang D., Vinograd J., Vosberg H. Action of nicking-closing enzyme on supercoiled and nonsupercoiled closed circular DNA: formation of a Boltzman distribution of topological isomers. Proc. Natl. Acad. Sci. USA. 72:1975;4280-4284.
12. Champoux J.J. Evidence for an intermediated with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme. Proc. Natl. Acad. Sci. USA. 73:1976;3488-3491.
13. L. Liu, DNA Topoisomerases: Topoisomerase-Targeted Drugs, Vol. 29, Academic Press, New York, 1994.
14. Corbett A.H., Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol. 6:1993;585-597.
15. Ferguson L.R., Baguley B.C. Topoisomerase II enzymes and mutagenicity. Environ. Mol. Mutagen. 24:1994;245-261.
16. Froelich-Ammon S.J., Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270:1995;21429-21432.
17. Y. Pommier, M.R. Fesen, F. Goldwasser, in: B.A. Chabner, D.L. Longo (Eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd edn., Lippincott-Raven, Philadelphia, PA, 1996, pp. 435-461.
18. Nitiss J.L., Beck W.T. Antitopoisomerase drug action and resistance. Eur. J. Cancer. 32a:1996;958-966.
19. Anderson R.D., Berger N.A. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat. Res. 309:1994;109-142.
20. Y. Pommier, in: B.A. Teicher (Ed.), Cancer Therapeutics: Experimental and Clinical Agents, Vol. I, Humana Press, Totowa, NJ, 1997, pp. 153-174.
21. C.H. Takimoto, S.G. Arbuck, in: B.A. Chabner, D.L. Longo (Eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice, 2 edn., Lippincott-Raven, Philadelphia, PA, 1996, pp. 463-484.
22. Kingma P.S., Corbett A.H., Burcham P.C., Marnett L.J., Osheroff N. Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II: anticancer drugs mimic endogenous DNA lesions. J. Biol. Chem. 270:1995;21441-21444.
23. Kingma P.S., Osheroff N. Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage. J. Biol. Chem. 272:1997;7488-7493.
24. Kingma P.S., Osheroff N. Apurinic sites are position-specific topoisomerase II-poisons. J. Biol. Chem. 272:1997;1148-1155.
25. Pourquier P., Ueng L.M., Kohlhagen G., Mazumder A., Gupta M., Kohn K.W., Pommier Y. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J. Biol. Chem. 272:1997;7792-7796.
26. Bigioni M., Zunino F., Tinelli S., Austin C.A., Willmore E., Capranico G. Position-specific effects of base mismatch on mammalian topoisomerase II-DNA cleaving activity. Biochemistry. 35:1996;153-159.
27. Lanza A., Tornaletti S., Rodolfo C., Scanavini M.C., Pedrini A.M. Human DNA topoisomerase I-mediated cleavages stimulated by ultraviolet light-induced DNA damage. J. Biol. Chem. 271:1996;6978-6986.
28. Yeh Y.C., Liu H.F., Ellis C.A., Lu A.L. Mammalian topoisomerase I has base mismatch nicking activity. J. Biol. Chem. 269:1994;15498-15504.
29. Stevnsner T., Mortensen U.H., Westergaard O., Bonven B.J. Interactions between eukaryotic DNA topoisomerase I and a specific binding sequence. J. Biol. Chem. 264:1989;10110-10113.
30. Rosenstein B.S., Subramanian D., Muller M.T. The involvement of topoisomerase I in the induction of DNA-protein crosslinks and DNA single-strand breaks in cells of ultraviolet-irradiated human and frog cell lines. Radiat. Res. 148:1997;575-579.
31. E.C., Friedberg, G.C. Walker, W. Siede, DNA Repair and Mutagenesis, 2nd edn., American Society for Microbiology Press, Washington, DC, 1995.
32. Lindahl T., Nyberg B. Rate of depurination of native deoxyribonucleic acid. Biochemistry. 11:1972;3610-3618.
33. Lindahl T. Instability and decay of the primary structure of DNA. Nature. 362:1993;709-715.
34. Fornace A.J. Jr., Kohn K.W., Kann H.E. Jr. DNA single-strand breaks during repair of UV damage in human fibroblasts and abnormalities of repair in xeroderma pigmentosum. Proc. Natl. Acad. Sci. USA. 73:1976;39-43.
35. Fornace A.J. Jr., Kohn K.W. DNA-protein cross-linking by ultraviolet radiation in normal human and xeroderma pigmentosum fibroblasts. Biochim. Biophys. Acta. 435:1976;95-103.
36. Rosenstein B.S., Rosenstein R.B., Zamansky G.B. Repair of DNA damage induced in systemic lupus erythematosus skin fibroblasts by simulated sunlight. J. Invest. Dermatol. 98:1992;469-474.
37. Rosenstein B.S., Lai L.W., Ducore J.M., Rosenstein R.B. DNA-protein crosslinking in normal and solar UV-sensitive ICR 2A frog cell lines exposed to solar UV-radiation. Mutat. Res. 217:1989;219-226.
38. Sage E. Distribution and repair of photolesions in DNA: genetic consequences and the role of sequence context. Photochem. Photobiol. 57:1993;163-174.
39. Pedrini A.M., Ciarrocchi G. Inhibition of Micrococcus luteus DNA topoisomerase I by UV photoproducts. Proc. Natl. Acad. Sci. USA. 80:1983;1787-1791.
40. Pedrini A.M. Effect of UV induced DNA lesions on the activity of Escherichia coli DNA topoisomerases: a possible role of these enzymes in DNA repair. Adv. Exp. Med. Biol. 179:1984;449-454.
41. Corbett A.H., Zechiedrich E.L., Lloyd R.S., Osheroff N. Inhibition of eukaryotic topoisomerase II by ultraviolet-induced cyclobutane pyrimidine dimers. J. Biol. Chem. 266:1991;19666-19671.
42. Kingma P.S., Greider C.A., Osheroff N. Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry. 36:1997;5934-5939.
43. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry. 28:1989;6157-6160.
44. Robinson M.J., Osheroff N. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry. 30:1991;1807-1813.
45. Raap J., Dreef C.E., van der Marel G.A., van Boom J.H., Hilbers C.W. Synthesis and proton-NMR studies of oligonucleotides containing an apurinic (AP) site. J. Biomol. Struct. Dynam. 5:1987;219-247.
46. Kalnik M.W., Chang C.N., Grollman A.P., Patel D.J. NMR studies of abasic sites in DNA duplexes: deoxyadenosine stacks into the helix opposite the cyclic analogue of 2-deoxyribose. Biochemistry. 27:1988;924-931.
47. Cuniasse P., Fazakerley G.V., Guschlbauer W. The abasic site as a challenge to DNA polymerase: a nuclear magnetic resonance study of G, C, and T opposite a model abasic site. J. Mol. Biol. 213:1990;303-314.
48. Carbonnaux C., Fazakerley G.V., Sowers L.C. An NMR structural study of deaminated base pairs in DNA. Nucleic Acids Res. 18:1990;4075-4081.
49. Singh M.P., Hill G.C., Peoc'h D., Rayner B., Imbach J.L., Lown J.W. High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry. 33:1994;10271-10285.
50. Goljer I., Kumar S., Bolton P.H. Refined solution structure of a DNA heteroduplex containing an aldehydic abasic site. J. Biol. Chem. 270:1995;22980-22987.
51. Kreuzer K.N., Cozzarelli N.R. Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J. Bacteriol. 140:1979;424-435.
52. Capranico G., Kohn K.W., Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 18:1990;6611-6619.
53. Capranico G., De Isabella P., Tinelli S., Bigioni M., Zunino F. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry. 32:1993;3038-3046.
54. Pommier Y., Capranico G., Orr A., Kohn K.W. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res. 19:1991;5973-5980.
55. Freudenreich C.H., Kreuzer K.N. Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc. Natl. Acad. Sci. USA. 91:1994;11007-11011.
56. Pommier Y., Kohlhagen G., Kohn K.W., Leteurtre F., Wani M.C., Wall M.E. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl. Acad. Sci. USA. 92:1995;8861-8865.
57. Froelich-Ammon S.J., Patchan M.W., Osheroff N., Thompson R.B. Topoisomerase II binds to ellipticine in the absence or presence of DNA: characterization of enzyme-drug interactions by fluorescence spectroscopy. J. Biol. Chem. 270:1995;14998-15005.
58. Burden D.A., Kingma P.S., Froelich-Ammon S.J., Bjornsti M.-A., Patchan M.W., Thompson R.B., Osheroff N. Topoisomerase II·etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J. Biol. Chem. 271:1996;29238-29244.
59. Hertzberg R.P., Caranfa M.J., Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 28:1989;4629-4638.
60. Ramotar D., Popoff S.C., Gralla E.B., Demple B. Cellular role of yeast Apn1 apurinic endonuclease/3′-diesterase: repair of oxidative and alkylation DNA damage and control of spontaneous mutation. Mol. Cell. Biol. 11:1991;4537-4544.
61. Spitzner J.R., Muller M.T. A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res. 16:1988;5533-5556.
62. Sander M., Hsieh T.S. Drosophila topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site. Nucleic Acids Res. 13:1985;1057-1072.
63. Nitiss J.L., Rose A., Sykes K.C., Harris J., Zhou J. Using yeast to understand drugs that target topoisomerases. Ann. New York Acad. Sci. 803:1996;32-43.
64. Christians F.C., Newcomb T.G., Loeb L.A. Potential sources of multiple mutations in human cancers. Prevent. Med. 24:1995;329-332.